Premium
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
AbbVie Reports Full-Year and Fourth-Quarter 2024 Financial Results PR Newswire NORTH CHICAGO, Ill., Jan. 31, 2025 Reports Full-Year Diluted EPS of $2.39 on a GAAP Basis, a Decrease of 12.1...
Allergan Aesthetics launches new AA Signature Program at IMCAS 2025 to redefine patient-centric, multimodal treatment plans PR Newswire NORTH CHICAGO, Ill., Jan. 29, 2025 AA Signature provides an...
Allergan Aesthetics unveils new AA Signature Program and immersive booth at IMCAS World Congress 2025 PR Newswire NORTH CHICAGO, Ill., Jan. 24, 2025 New AA (Allergan Aesthetics) Signature Program...
AbbVie Completes Acquisition of Nimble Therapeutics PR Newswire NORTH CHICAGO, Ill., Jan. 23, 2025 Acquisition adds potential novel oral peptide IL23R inhibitor for psoriasis as well as a peptide...
AbbVie and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology PR Newswire NORTH CHICAGO, Ill. and SAN DIEGO, Jan. 23, 2025 Collaboration...
AbbVie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma PR Newswire NORTH CHICAGO, Ill. and SHANGHAI, Jan. 13, 2025 NORTH CHICAGO...
AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program PR Newswire NORTH CHICAGO, Ill. and ROCKVILLE, Md., Jan. 13, 2025 Pivotal data evaluating the safety and efficacy of the...
AbbVie to Present at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire NORTH CHICAGO, Ill., Jan. 9, 2025 NORTH CHICAGO, Ill., Jan. 9, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
